1. Scrip
  2. >>Business
  3. >>Deals

Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

 
• By Joseph Haas

Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.

Mergers
Supernus adds to its CNS portfolio with $400m buyout of Adamas

Supernus Pharmaceuticals, Inc. announced that it will acquire Adamas Pharmaceuticals, Inc. and its slow-growing Parkinson’s disease drug Gocovri on 11 October in a deal that will broaden Supernus’s portfolio in the central nervous system arena and leverage its existing commercial structure to support Gocovri in two Parkinson’s-related indications.

One analyst called it a sensible transaction for both sides, as Supernus will pay $400m up front, with contingent value rights that could

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.